An Open-label, Multiple Dose, Cross-over Study to Evaluate the Steady-state Pharmacokinetic Parameters of Nevirapine Extended Release Tablets in HIV-1 Infected Children, With an Optional Extension Phase.
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2016
At a glance
- Drugs Nevirapine (Primary) ; Nevirapine (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 01 Jun 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2008-005855-61).
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.